CRNX - CIK 0001658247
Crinetics Pharmaceuticals, Inc. (CRNX) reported net income of -$465.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$465.30M | -55.9% |
| FY 2024 | -$298.40M | -39.1% |
| FY 2023 | -$214.50M | -30.9% |
| FY 2022 | -$163.90M | -52.3% |
| FY 2021 | -$107.60M | -45.8% |
| FY 2020 | -$73.81M | -46.4% |
| FY 2019 | -$50.42M | -86.0% |
| FY 2018 | -$27.11M | -196.1% |
| FY 2017 |
Crinetics Pharmaceuticals, Inc. (CRNX) reported net income of -$465.30M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Crinetics Pharmaceuticals, Inc.'s net income declined from -$6.02M to -$465.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$9.16M |
| -52.1% |
| FY 2016 | -$6.02M | - |